Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy

To determine whether treatment with the anti-TNF-alpha blocker adalimumab yields persistent improvement of endothelial function and prevents from morphological progression of subclinical atherosclerosis in patients with rheumatoid arthritis (RA) refractory to conventional therapy, a series of 34 con...

Descripción completa

Detalles Bibliográficos
Autores: González Juanatey, Carlos, Vázquez Rodríguez, Tomás R., Miranda Filloy, José Alberto, Gómez Acebo, Inés|||0000-0001-8793-8314, Testa, Ana, García Porrúa, Carlos, Sánchez Andrade, Amalia, Llorca Díaz, Javier, González-Gay Mantecón, Miguel Ángel|||0000-0002-7924-7406
Tipo de recurso: artículo
Fecha de publicación:2012
País:España
Institución:Universidad de Cantabria (UC)
Repositorio:UCrea Repositorio Abierto de la Universidad de Cantabria
Idioma:inglés
OAI Identifier:oai:repositorio.unican.es:10902/1164
Acceso en línea:http://hdl.handle.net/10902/1164
Access Level:acceso abierto
id ES_73e3358410833a67183db2ceffbe4d02
oai_identifier_str oai:repositorio.unican.es:10902/1164
network_acronym_str ES
network_name_str España
repository_id_str
spelling Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapyGonzález Juanatey, CarlosVázquez Rodríguez, Tomás R.Miranda Filloy, José AlbertoGómez Acebo, Inés|||0000-0001-8793-8314Testa, AnaGarcía Porrúa, CarlosSánchez Andrade, AmaliaLlorca Díaz, JavierGonzález-Gay Mantecón, Miguel Ángel|||0000-0002-7924-7406To determine whether treatment with the anti-TNF-alpha blocker adalimumab yields persistent improvement of endothelial function and prevents from morphological progression of subclinical atherosclerosis in patients with rheumatoid arthritis (RA) refractory to conventional therapy, a series of 34 consecutive RA patients, attending hospital outpatient clinics and who were switched from disease modifying antirheumatic drug therapy to anti-TNF-alpha-adalimumab treatment because of severe disease, were assessed by ultrasonography techniques before the onset of adalimumab therapy (at day 0) and then at day 14 and at month 12. Values of flow-mediated endothelium-dependent vasodilatation at day 14 and at month 12 were significantly higher (mean ± standard deviation (SD): 6.1 ± 3.9%; median: 5.7% at day 14, and mean ± SD: 7.4 ± 2.8%; median: 6.9% at month 12) than those obtained at day 0 (mean: 4.5 ± 4.0%; median: 3.6%; P = 0.03 and P < 0.001, resp.). Endothelium-independent vasodilatation results did not significantly change compared with those obtained at day 0. No significant differences were observed when carotid artery intima-media wall thickness values obtained at month 12 (mean ± SD: 0.69 ± 0.21 mm) were compared with those found at day 0 (0.65 ± 0.16 mm) (P = 0.3). In conclusion, anti-TNF-alpha-adalimumab therapy has beneficial effects on the development of the subclinical atherosclerosis disease in RA.Hindawi Publishing CorporationUniversidad de Cantabria20122012-07-31journal articlehttp://purl.org/coar/resource_type/c_6501NAhttp://purl.org/coar/version/c_be7fb7dd8ff6fe43info:eu-repo/semantics/articlehttp://hdl.handle.net/10902/1164Mediators of Inflammation. 2012;2012:674265. Epub 2012 jul 31.reponame:UCrea Repositorio Abierto de la Universidad de Cantabriainstname:Universidad de Cantabria (UC)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Atribución 3.0 Españahttp://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:repositorio.unican.es:10902/11642026-06-02T12:39:31Z
dc.title.none.fl_str_mv Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy
title Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy
spellingShingle Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy
González Juanatey, Carlos
title_short Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy
title_full Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy
title_fullStr Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy
title_full_unstemmed Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy
title_sort Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy
dc.creator.none.fl_str_mv González Juanatey, Carlos
Vázquez Rodríguez, Tomás R.
Miranda Filloy, José Alberto
Gómez Acebo, Inés|||0000-0001-8793-8314
Testa, Ana
García Porrúa, Carlos
Sánchez Andrade, Amalia
Llorca Díaz, Javier
González-Gay Mantecón, Miguel Ángel|||0000-0002-7924-7406
author González Juanatey, Carlos
author_facet González Juanatey, Carlos
Vázquez Rodríguez, Tomás R.
Miranda Filloy, José Alberto
Gómez Acebo, Inés|||0000-0001-8793-8314
Testa, Ana
García Porrúa, Carlos
Sánchez Andrade, Amalia
Llorca Díaz, Javier
González-Gay Mantecón, Miguel Ángel|||0000-0002-7924-7406
author_role author
author2 Vázquez Rodríguez, Tomás R.
Miranda Filloy, José Alberto
Gómez Acebo, Inés|||0000-0001-8793-8314
Testa, Ana
García Porrúa, Carlos
Sánchez Andrade, Amalia
Llorca Díaz, Javier
González-Gay Mantecón, Miguel Ángel|||0000-0002-7924-7406
author2_role author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidad de Cantabria
description To determine whether treatment with the anti-TNF-alpha blocker adalimumab yields persistent improvement of endothelial function and prevents from morphological progression of subclinical atherosclerosis in patients with rheumatoid arthritis (RA) refractory to conventional therapy, a series of 34 consecutive RA patients, attending hospital outpatient clinics and who were switched from disease modifying antirheumatic drug therapy to anti-TNF-alpha-adalimumab treatment because of severe disease, were assessed by ultrasonography techniques before the onset of adalimumab therapy (at day 0) and then at day 14 and at month 12. Values of flow-mediated endothelium-dependent vasodilatation at day 14 and at month 12 were significantly higher (mean ± standard deviation (SD): 6.1 ± 3.9%; median: 5.7% at day 14, and mean ± SD: 7.4 ± 2.8%; median: 6.9% at month 12) than those obtained at day 0 (mean: 4.5 ± 4.0%; median: 3.6%; P = 0.03 and P < 0.001, resp.). Endothelium-independent vasodilatation results did not significantly change compared with those obtained at day 0. No significant differences were observed when carotid artery intima-media wall thickness values obtained at month 12 (mean ± SD: 0.69 ± 0.21 mm) were compared with those found at day 0 (0.65 ± 0.16 mm) (P = 0.3). In conclusion, anti-TNF-alpha-adalimumab therapy has beneficial effects on the development of the subclinical atherosclerosis disease in RA.
publishDate 2012
dc.date.none.fl_str_mv 2012
2012-07-31
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
NA
http://purl.org/coar/version/c_be7fb7dd8ff6fe43
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/10902/1164
url http://hdl.handle.net/10902/1164
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atribución 3.0 España
http://creativecommons.org/licenses/by/3.0/es/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atribución 3.0 España
http://creativecommons.org/licenses/by/3.0/es/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Hindawi Publishing Corporation
publisher.none.fl_str_mv Hindawi Publishing Corporation
dc.source.none.fl_str_mv Mediators of Inflammation. 2012;2012:674265. Epub 2012 jul 31.
reponame:UCrea Repositorio Abierto de la Universidad de Cantabria
instname:Universidad de Cantabria (UC)
instname_str Universidad de Cantabria (UC)
reponame_str UCrea Repositorio Abierto de la Universidad de Cantabria
collection UCrea Repositorio Abierto de la Universidad de Cantabria
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869410842519273472
score 15.301603

Similares en LA Referencia